Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vebreltinib in c-Met-dysregulated Advanced NSCLC
NCT02929290Phase 1Unknown
- Sponsor
- Betta Pharmaceuticals
- Start
- Mar 2017
- Primary completion
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of vebreltinib in non-small cell lung cancer (NSCLC), sponsored by Betta Pharmaceuticals. Primary endpoints: Participants with Adverse Events at 18 months, Objective Response Rate at 16 weeks and 1 more. Status: unknown.
02
Drugs
vebreltinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02929290.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02929290.